I-Mab to Present Clinical Data of Lemzoparlimab in Combinati

- Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed in collaboration with AbbVie


- Initial clinical results of lemzoparlimab in... | November 4, 2021

Related Keywords

Guangzhou , Guangdong , China , Shanghai , United States , Hong Kong , Lishui , Zhejiang , Beijing , Gaithersburg , Maryland , San Diego , California , Hangzhou , American , Emilie Wu , Amitkumar Mehta , Gigi Feng , John Long , Company Nasdaq , American Society Of Hematology Annual Meeting , Linkedin , Twitter , Georgia World Congress Center , Piacente Group Inc , University Of Alabama At Birmingham , Nasdaq , Exchange Commission , American Society , Hematology Annual Meeting , Refractory Non Hodgkin , Initial Clinical , World Congress Center , Private Securities Litigation Reform Act , Piacente Group , I Mab Stock Exchange , News , Information , Press Release , Emzoparlimab , Us , Differentiated , Cd47 , Monoclonal , Ntibody , Iscovered , Y , End , Being , Eveloped , N , Collaboration , Ith , Nitial , Linical , Results , F , Emzoparlimab Imab Us44975p1030 ,